EULAR recommendations for the management of Behçet’s syndrome: 2025 update
Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 1010-1025
DOI: 10.1016/j.ard.2026.02.009 ↗Kurz gefasst
Leitlinie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Gulen Hatemi und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Istanbul, Türkiye; Behçet's D…. Hauptthemen laut MEDLINE: Behcet Syndrome, Immunosuppressive Agents. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Alliance of Associations for Rheumatology.
Abstract (Originalsprache)
OBJECTIVES: This study aims to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Behçet's syndrome according to the updated EULAR standard operating procedures. METHODS: The task force comprised 29 members from 11 countries, including 19 rheumatologists, 2 ophthalmologists, 1 dermatologist, 1 gastroenterologist, 1 neurologist, 1 health professional, 2 patient research partners, and 2 Emerging EUlar NETwork members. Research questions were proposed by the task force through a Delphi survey and formulated into patients, interventions, comparison, and outcomes (PICO) questions for the systematic literature review. The results of the systematic literature review were discussed among the task force members. Previous recommendations and overarching principles were modified, and new recommendations were developed as needed. The updated recommendations were voted, and the levels of evidence and levels of agreement were determined. RESULTS: The updated recommendations consist of 5 overarching principles and 12 recommendations that were tabulated according to organ involvement. Among the 12 recommendations, 1 was a new recommendation, 7 recommendations were modified, and only the wording was changed in 4 recommendations. The overarching principles focus on the importance of recognising the relapsing and remitting disease course and individualising treatment according to disease activity and prognostic risk factors, and emphasise the importance of a multidisciplinary approach, patient education, and shared decision making for optimal care. For mucocutaneous and joint involvement, colchicine is recommended as the first-line treatment modality. Apremilast and immunosuppressives such as tumour necrosis factor alpha (TNFα) inhibitors are recommended for refractory patients. For patients with organ involvement, more aggressive treatment with glucocorticoids and immunosuppressives is recommended for rapid induction of remission. Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations. CONCLUSIONS: These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University - Cerrahpasa, Istanbul, Türkiye; Behçet's Disease Research Center, Istanbul University - Cerrahpasa, Istanbul, Tü…
- Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; Zuyderland Medical Center, Heerlen, Netherlands.
- Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Internal Medicine and Emergency Services, Landspitali-The National University Hospital of Icel…
- Department of Dermatology, Pitié-Salpêtrière University Hospital, Sorbonne University, Paris, France.
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
- Department of Ophthalmology, Reference Center for Rare Diseases, Pitié-Salpêtrière Hospital, APHP-Sorbonne University, Paris, France.
Förderung
- European Alliance of Associations for Rheumatology
Zitieren
APA
Hatemi, G., Ramiro, S., Ozguler, Y., Esatoglu, S. N., Tomasson, G., Barete, S., Bettiol, A., Bodaghi, B., Boyadzhieva, V., Cantarini, L., Celik, A. F., Dhrif, O., Ducker, G., Emmi, G., Gül, A., Henes, J., Koetter, I., Krusche, M., Lopalco, G., …, & Yazici, H. (2026). EULAR recommendations for the management of Behçet’s syndrome: 2025 update. Annals of the Rheumatic Diseases, 85(6), 1010-1025. https://doi.org/10.1016/j.ard.2026.02.009
Vancouver
Hatemi G, Ramiro S, Ozguler Y, Esatoglu SN, Tomasson G, Barete S, et al. EULAR recommendations for the management of Behçet’s syndrome: 2025 update. Annals of the Rheumatic Diseases. 2026;85(6):1010-1025. doi:10.1016/j.ard.2026.02.009
BibTeX
@article{Hatemi2026,
author = {Hatemi, Gulen and Ramiro, Sofia and Ozguler, Yesim and Esatoglu, Sinem Nihal and Tomasson, Gunnar and Barete, Stephane and Bettiol, Alessandra and Bodaghi, Bahram and Boyadzhieva, Vladimira and Cantarini, Luca and Celik, Aykut Ferhat and Dhrif, Omar and Ducker, Georgina and Emmi, Giacomo and Gül, Ahmet and Henes, Jörg and Koetter, Ina and Krusche, Martin and Lopalco, Giuseppe and Moots, Robert J and Saadoun, David and Salvarani, Carlo and Sfikakis, Petros and Stefanovic, Aleksandra and Talarico, Rosaria and Tugal-Tutkun, Ilknur and Uygunoglu, Ugur and Zhao, Qianyu and Yazici, Hasan},
title = {EULAR recommendations for the management of Behçet’s syndrome: 2025 update},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {6},
pages = {1010--1025},
doi = {10.1016/j.ard.2026.02.009}
}
EUVIMED